1
|
Estrada N, Zamora L, Ferrer-Marín F, Palomo L, García O, Vélez P, De la Fuente I, Sagüés M, Cabezón M, Cortés M, Vallansot RO, Senín-Magán MA, Boqué C, Xicoy B. Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients. J Clin Med 2022; 11:jcm11206217. [PMID: 36294538 PMCID: PMC9604607 DOI: 10.3390/jcm11206217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 10/14/2022] [Accepted: 10/17/2022] [Indexed: 12/02/2022] Open
Abstract
Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal therapeutic strategy (imatinib vs. more potent second-generation TKIs). The aim of this retrospective study was to understand the contribution of germline single-nucleotide variants (gSNVs) in the achievement of MMR with imatinib. In particular, a discovery cohort including 45 CP-CML patients was analyzed through the DMET array, which interrogates 1936 variants in 231 genes related to the absorption, distribution, metabolism and excretion (ADME) process. Variants statistically significant in the discovery cohort were then tested in an extended and independent cohort of 137 CP-CML patients. Finally, a total of 7 gSNVs (ABCG1-rs492338, ABCB11-rs496550, ABCB11-rs497692, CYP2D6-rs1135840, CYP11B1-rs7003319, MAT1A-rs4934027 and SLC22A1-rs628031) and one haplotype in the ABCB11 gene were significantly associated with the achievement of MMR with first-line imatinibtreatment. In conclusion, we identified a genetic signature of response to imatinib in CP-CML patients that could be useful in selecting those patients that may benefit from starting imatinib as first-line therapy, therefore avoiding the toxicity related to second-generation TKIs.
Collapse
Affiliation(s)
- Natalia Estrada
- Myeloid Neoplasms Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
| | - Lurdes Zamora
- Myeloid Neoplasms Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
- Correspondence:
| | - Francisca Ferrer-Marín
- Hospital General Universitario Morales Meseguer, CIBERER (CB15/00055), IMIB-Pascual Parrilla, UCAM, 30008 Murcia, Spain
| | - Laura Palomo
- MDS Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
- Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Olga García
- Myeloid Neoplasms Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
| | | | | | | | - Marta Cabezón
- Myeloid Neoplasms Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
| | | | | | | | | | - Blanca Xicoy
- Myeloid Neoplasms Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
| |
Collapse
|
2
|
Martinez Marti A, Cabrera G, Ortiz C, Vilaro M, Miquel JM, Cedres Perez S, Navarro A, Pardo Aranda N, Martinez P, Piera A, Carbonell LL, De la Fuente I, Garcia S, Sansano I, Felip E. Results of patients with thoracic cancers older than 70 years included in clinical trials: A center experience. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e20582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Alex Martinez Marti
- Medical Oncology Department Vall d´Hebron Institute of Oncology-Vall D'Hebron University Hospital, Barcelona, Spain
| | | | | | - Marta Vilaro
- Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | - Alejandro Navarro
- Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Nuria Pardo Aranda
- Medical Oncology Department Vall d'Hebron Institute of Oncology-Vall d´Hebron University Hospital, Barcelona, Spain
| | - Pablo Martinez
- Medical Oncology Department, Clinica Diagonal, Barcelona, Spain
| | - Adelaida Piera
- Medical Oncology Department Vall d'Hebron Institute of OncologyVall d´Hebron University Hospital, Barcelona, Spain
| | - LLuisa Carbonell
- Medical Oncology Department Vall d'Hebron Institute of OncologyVall d´Hebron University Hospital, Barcelona, Spain
| | - Iris De la Fuente
- Study Coordinator, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Silvia Garcia
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Irene Sansano
- Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | | |
Collapse
|